What is Solid Biosciences?
Solid Biosciences is a prominent life sciences entity dedicated to advancing a comprehensive portfolio of gene therapy candidates. The company's focus spans critical therapeutic areas, including SGT-003 for Duchenne muscular dystrophy, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and AVB-401 for BAG3-mediated dilated cardiomyopathy. Additionally, Solid Biosciences is developing assets targeting fatal cardiac diseases. By assembling a multidisciplinary team of experts in science, technology, disease management, and patient care, the company aims to address rare neuromuscular and cardiac conditions. Founded with a patient-centric mandate, Solid Biosciences is committed to enhancing the quality of life for individuals affected by these severe diseases.
How much funding has Solid Biosciences raised?
Solid Biosciences has raised a total of $455M across 3 funding rounds:
Stock Offering
$125M
Share Placement
$90M
Stock/Share Issuance
$240M
Stock Issuance/Offering (2018): $125M, investors not publicly disclosed
Share Placement (2020): $90M led by EcoR1 Capital, RA Capital Management, Boxer Capital, Suvretta Capital Management, Perceptive Advisors, Aspire Capital Fund, Bain Capital, and Ikarian Capital
Stock/Share Issuance (2026): $240M, investors not publicly disclosed
Key Investors in Solid Biosciences
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, aiming to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation and developing new medicines.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs and medical devices. They aim to partner with innovators to bring ideas from the lab to the clinic.
Bain Capital
Founded in 1984, Bain Capital is one of the worlds leading private investment firms committed to creating lasting impact for its investors and portfolio businesses. The firm invests across Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets.
What's next for Solid Biosciences?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Solid Biosciences. This capital infusion is expected to fuel the advancement of its gene therapy pipeline, potentially accelerating clinical trials and regulatory submissions for its key candidates. The company's focus on rare and devastating diseases, coupled with its patient-first approach, positions it for significant impact. Future developments will likely involve expanding its therapeutic reach, forging strategic partnerships, and continuing its mission to deliver life-changing treatments to patients worldwide.
See full Solid Biosciences company page
